Unknown

Dataset Information

0

Assessment of NSAIDs as potential inhibitors of the fatty acid amide hydrolase I (FAAH-1) using three different primary fatty acid amide substrates in vitro.


ABSTRACT:

Background

Pain relief remains a major subject of inadequately met need of patients. Therapeutic agents designed to treat pain and inflammation so far have low to moderate efficiencies with significant untoward side effects. FAAH-1 has been proposed as a promising target for the discovery of drugs to treat pain and inflammation without significant adverse effects. FAAH-1 is the primary enzyme accountable for the degradation of AEA and related fatty acid amides. Studies have revealed that the simultaneous inhibition of COX and FAAH-1 activities produce greater pharmacological efficiency with significantly lowered toxicity and ulcerogenic activity. Recently, the metabolism of endocannabinoids by COX-2 was suggested to be differentially regulated by NSAIDs.

Methods

We analysed the affinity of oleamide, arachidonamide and stearoylamide at the FAAH-1 in vitro and investigated the potency of selected NSAIDs on the hydrolysis of endocannabinoid-like molecules (oleamide, arachidonamide and stearoylamide) by FAAH-1 from rat liver. NSAIDs were initially screened at 500 μM after which those that exhibited greater potency were further analysed over a range of inhibitor concentrations.

Results

The substrate affinity of FAAH-1 obtained, increased in a rank order of oleamide < arachidonamide < stearoylamide with resultant Vmax values in a rank order of arachidonamide > oleamide > stearoylamide. The selected NSAIDs caused a concentration-dependent inhibition of FAAH-1 activity with sulindac, carprofen and meclofenamate exhibiting the greatest potency. Michaelis-Menten analysis suggested the mode of inhibition of FAAH-1 hydrolysis of both oleamide and arachidonamide by meclofenamate and indomethacin to be non-competitive in nature.

Conclusion

Our data therefore suggest potential for study of these compounds as combined FAAH-1-COX inhibitors.

SUBMITTER: Dongdem JT 

PROVIDER: S-EPMC8725537 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6072049 | biostudies-literature
| S-EPMC3359644 | biostudies-other
| S-EPMC3150822 | biostudies-literature
| S-EPMC3088576 | biostudies-literature
| S-EPMC6009913 | biostudies-literature
| S-EPMC8306898 | biostudies-literature
| S-EPMC5063142 | biostudies-literature
| S-EPMC4613608 | biostudies-literature
| S-EPMC4025847 | biostudies-other
| S-EPMC3678964 | biostudies-literature